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Histone deacetylase inhibitors (HDACIs) are being investigated as novel therapies for
cancer, inﬂammation, neurodegeneration, and heart failure. The effects of HDACIs on
the functional expression of cardiac gap junctions (GJs) are essentially unknown. The
purpose of this study was to determine the effects of trichostatin A (TSA) and vorinostat
(VOR) on functional GJ expression in ventricular cardiomyocytes. The effects of HDAC
inhibition on connexin43 (Cx43) expression and functional GJ assembly were examined
in primary cultured neonatal mouse ventricular myocytes. TSA and VOR reduced Cx43
mRNA, protein expression, and immunolocalized Cx43 GJ plaque area within ventricular
myocyte monolayer cultures in a dose-dependent manner. Chromatin immunoprecipitation
experiments revealed altered protein interactions with the Cx43 promoter. VOR also
altered the phosphorylation state of several key regulatory Cx43 phospho-serine sites.
Patch clamp analysis revealed reduced electrical coupling between isolated ventricular
myocyte pairs, altered transjunctional voltage-dependent inactivation kinetics, and steady
state junctional conductance inactivation and recovery relationships. Single GJ channel
conductance was reduced to 54 pS only by maximum inhibitory doses of TSA (≥100 nM).
These two hydroxamate pan-HDACIs exert multiple levels of regulation on ventricular GJ
communication by altering Cx43 expression, GJ area, post-translational modiﬁcations
(e.g., phosphorylation, acetylation), gating, and channel conductance. Although a 50%
downregulation of Cx43 GJ communication alone may not be sufﬁcient to slow ventricular
conduction or induce arrhythmias, the development of class-selective HDACIs may help
avoid the potential negative cardiovascular effects of pan-HDACI.
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INTRODUCTION
Histone acetyltransferases (HATs) and deacetylases (HDACs) reg-
ulate the nuclear protein acetylation–deacetylation cycle that
modulates gene expression by altering chromatin condensation
and transcription factor [e.g., MEF2 (myocyte enhancer factor-2),
p53] activities (Kouzarides, 2000; Yang and Grégoire, 2007; Yang
and Seto, 2008; Haberland et al., 2009). Several cytosolic pro-
teins have been identiﬁed as substrates for the HAT/HDAC protein
acetylation cycle (e.g., tubulin; Piperno et al., 1987; Yang and Gré-
goire, 2007). There are 11 highly homologousmammalianHDACs
containing Zn2+-dependent catalytic deacetylase (DAC) domains,
subdivided into three classes based on their divergent amino-
and carboxyl-terminal domains. The class I HDACs (HDAC1–3
and 8) consist primarily of a single DAC with short amino and
carboxyl-termini, as does the class IV HDAC (HDAC11; Yang and
Seto, 2008). The class IIa HDACs (HDAC4, 5, 7, and 9) possess
amino-terminal MEF2 and 14-3-3 protein binding motifs and
shuttle between the nucleus and cytosol in a phosphorylation-
dependent manner (McKinsey et al., 2000; Zhou et al., 2000; Little
et al., 2007). Phosphorylation of HDAC4, 5, and 9 promotes the
expression of cardiac prohypertrophic genes and their deletion
increases susceptibility to stress-induced hypertrophy (Little et al.,
2007; Yang and Seto, 2008; Haberland et al., 2009). HDAC4 is
implicated in the regulation of cardiac contractility via muscle
LIM protein (MLP) acetylation (Gupta et al., 2008). The class
IIb HDAC6 is unique in that it possesses two DAC domains and
deacetylates tubulin along with sirtuins (SIRT2) (SIRT1–7 are the
NAD-dependent class III HDACs; Hubbert et al., 2002; Haber-
land et al., 2009). The function of the class IIb HDAC10 is poorly
understood.
Histone DAC inhibitors (HDACIs) are known to induce diverse
biological responses including apoptosis and cell-cycle arrest
(Rasheed et al., 2007). HDACI chemical subgroups include, in
order of potency, hydroxamic acids, cyclic peptides, benzamides,
electrophilic ketones, and short chain fatty acids. Trichostatin
A (TSA) is a biological hydroxamate compound with antibac-
terial, antifungal, and antiproliferative activities attributed to its
HDAC inhibitory activity (Yoshida et al., 1990). Two HDACIs have
received FDA approval for treating cutaneous T cell lymphoma
(CTCL) and there are >140 ongoing HDACI clinical trials as
novel therapeutics for numerous diseases including other forms
of cancer, neurodegeneration, inﬂammation, and heart failure
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(www.clinicaltrials.gov; Marks and Breslow, 2007; Rasheed et al.,
2007; Kazantsev and Thompson, 2008; Haberland et al., 2009;
Ryan, 2009; Shakespear et al., 2011; McKinsey, 2012). Vorinostat
[VOR, suberoylanilide hydroxamic acid (SAHA), ZolinzaTM] and
romidepsin (depsipeptide, FK-228, IstodaxTM) are relatively non-
selective pan-HDACIs despite possessing differential inhibitory
potencies for class IIa HDACs (Rasheed et al., 2007; Bradner
et al., 2010). Their broad spectrum HDACI proﬁles produce dose
limiting toxicities such as fatigue, thrombocytopenia, gastroin-
testinal toxicity, and QT interval prolongation (Rasheed et al.,
2007; McKinsey, 2011). Dose-dependent toxicities and increased
susceptibility to ventricular arrhythmias associated with some
HDACI therapies have emphasized the need to develop isoform
selective HDACIs (Shah et al., 2006; McKinsey, 2011).
Vorinostat reduced the occurrence of restraint-induced ventric-
ular arrhythmias in Duchenne muscular dystrophic (mdx) mice
(Colussi et al., 2010). However, mdx mouse hearts exhibit reduced
cardiac sodium channel (NaV1.5) expression and connexin43
(Cx43) lateralization owing to a hyperacetylated condition that
was reversed byVOR (Colussi et al., 2010, 2011). In wild-type (wt)
mouse hearts, VOR increased Cx43 acetylation and lateralization,
consistent with observations from the mdx mouse that increased
protein acetylation leads to Cx43 dissociation from N-cadherin
(Ncad), zonula occludens-1 (ZO-1), and cardiac intercalated disks,
and increased c-Src-dependent Y265 phosphorylation, molecu-
lar events known to downregulate Cx43-mediated gap junction
(GJ) communication (Colussi et al., 2011). Functional assess-
ment of ventricular electrical coupling is difﬁcult to perform in
intact heart, but is directly quantiﬁable by dual whole cell patch
clamp analysis in isolated cardiomyocyte cell pairs (Lin et al., 2005,
2008a, 2010).
This study was performed to examine the functional effects
of TSA and VOR on ventricular Cx43 GJs. Previous preliminary
ﬁndings suggested that Cx43 is acetylated and that treatment of
primary neonatal mouse ventricular myocyte cultures with TSA
reduced electrical coupling by nearly 50% (Hertzberg and Spektor,
2004; Lin et al., 2008b). We assessed the ability of TSA and VOR
to inhibit total ventricular HDAC activity using a ﬂuorimetric
assay; measured Cx43 and Ncad mRNA and protein levels; deter-
mined the phospho-serine (pSer) state of Cx43; quantiﬁed the
Cx43 GJ plaque area; and measured the GJ conductance (g j), tran-
sjunctional voltage (V j) gating, and single ventricular GJ channel
conductance (γj) properties in ventricular cardiomyocyte cultures
by patch clamp techniques. These results provide the ﬁrst direct
evidence for the functional downregulation of Cx43 GJ-mediated
electrical coupling between normal ventricular myocytes by pan-
HDAC inhibition. These effects presumably result from indirect
and direct effects of HDACI-induced increased protein acetylation
on Cx43 expression, GJ assembly, and function.
MATERIALS AND METHODS
CELL CULTURE
Newborn C57Bl/6 mice were anesthetized with isoﬂurane and the
hearts excised in accordance with procedures approved by the
institution’s Committee for the Humane Use of Animals. Neonatal
murine atrial and ventricular tissues were dissociated separately
in a Ca2+- and Mg2+-free collagenase balanced salt solution
(dulbecco’s modiﬁed saline [DMS8], in mM: NaCl, 116; KCl, 5.4,
NaH2PO4, 1.0; anddextrose, 5.5) containing≈1mg/ml of puriﬁed
collagenase (type II), 5.5 μg/ml deoxyribonuclease I (Worthing-
ton Biochemical Corp., Lakewood, NJ, USA), and 1 mg/ml bovine
serum albumin (BSA, fractionV, Sigma Chemical Corp., St. Louis,
MO, USA; Lin et al., 2005, 2008a, 2010). A total of ﬁve 10-min
dissociation cycles at 37◦C were performed using 5 ml of dis-
sociation solution/cycle. The supernatant from the ﬁrst cycle was
discarded and the supernatant from the remaining four cycles were
ﬁltered through a 70-μ cell strainer (Falcon, Franklin Lakes, NJ,
USA) into 5 ml of M199 cell culture media supplemented with
10% fetal bovine serum (FBS; Atlanta Biologicals) and 100 U/ml
penicillin/streptomycin (Invitrogen). Cell pellets were produced
by low speed centrifugation (500 rpm, 5 min) and resuspended
in M199/FBS media. The primary cell cultures were enriched for
cardiomyocytes by a 30-min differential cell adhesion step. The
cell media was collected, pelleted by low speed centrifugation,
and resuspended in approximately 1 ml of media per dissociated
heart ventricles. Approximately 0.1 ml of the ventricular myocyte
cell suspension was added to each 35 mm diameter culture dish
for patch clamp electrophysiology experiments. The remainder
of the ventricular cell suspension was divided between two 35-
mm culture dishes or four 12-wells containing ﬁbronectin-coated
coverslips for real-time (RT)-PCR, immunoblotting, immunopre-
cipitation, or immunostaining procedures. Exact cell counts were
obtained with a hemocytometer for plating cells in 96-well plates
for ﬂuorimetric HDAC activity assays. The media was exchange
daily and 200 μM bromodeoxyuridine (BrDU) was added on cul-
ture day 2 to the high density myocyte cultures to inhibit ﬁbroblast
proliferation. Stable transfectants of HeLa cells with rat Cx43
(HeLa-Cx43 cells) were prepared and cultured as described for
mouse Neuro2a (N2a) cells (Lin et al., 2003).
HDAC ACTIVITY ASSAYS
Aliquots of 6 × 10+5 ventricular myocytes or HeLa cells per well
(96-well plate) were grown in 200 μl of 200 μM BrDU/M199 or
N2a culture media, exchanged daily. Cells densities were counted
with a hemocytometer. Cell wells were incubated with 2,000 pmol
of the acetylated Fluor-de-Lys substrate for 6 h during HDAC
inhibition. Cell, media, and standard curve deacetylated sub-
strate sample wells were developed according to manufacturer’s
directions and background subtracted relative ﬂuorescence unit
(RFU) counts were acquired with a BIO-TEK Synergy plate reader
(360 nm excitation, 460 nm emission). A standard curve was gen-
erated using serial 1:10 dilutions of the deacetylated Fluor-de-Lys
standard and developer supplied with the BML-AK503 HDAC
ﬂuorometric cellular activity assay kit (Figure 1D; Enzo Life
Sciences). TSA was purchased from Calbiochem or Enzo Life Sci-
ences. VOR (SAHA,ZolinzaTM) was initially obtained from Merck
HDAC Research, LLC via a Material Transfer Agreement (MTA)
for in vitro use only andwas subsequently purchased commercially
from Selleck Chemicals, LLC.
REAL-TIME PCR
Total atrial or ventricular RNA was isolated with Qiagen
RNeasy mini kit, quantiﬁed by UV absorption, and 500 ng
reverse-transcribed with QuantiTect Reverse Transcription kit
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FIGURE 1 |Ventricular HDAC expression and inhibition. (A)The mRNA
expression levels for all 11 mammalian HDACs and two connexins, Cx43 and
Cx40, were detected by real-time PCR using the SYBR GreenERTM qPCR
SuperMix (Invitrogen) and custom-designed forward and reverse primers. The
data was averaged from three experiments. (B,C)Total HDAC activity was
measured in ventricular myocyte and stable Cx43-transfected HeLa cell
(HeLa-Cx43) cultures by deacetylated Fluor-de-Lys ﬂuorescence during
trichostatin A (TSA) (B) or vorinostat (VOR) inhibition (C). All data were
normalized to the background subtracted maximum relative ﬂuorescence of
the control well. The data from three experiments were averaged and ﬁtted
with a second-order exponential decaying function in Origin7.5 and the
equilibrium inhibition constants (K I) were calculated from the expression
K I = 0.693/[HDACI]decay constant. (D) A series of 1:10 dilutions of the
deacetylated Fluor-de-Lys substrate were combined with the developer
and ﬂuorescence counts were obtained with the BIO-TEK Synergy plate
reader in conjunction (i.e., parallel) with the cell-based HDAC activity
assays. The background (empty well) subtracted ﬂuorescence emission at
460 nm increased linearly with the concentration of the deacetylated
substrate. The experiments were performed in triplicate (mean ±
SEM).
(Qiagen). Fifty nanograms of the cDNA reaction mix was com-
bined with equal (nM) amounts of custom forward (5′–3′)
and reverse (3′–5′) RT-PCR primers, Superscript enzyme mix,
and SYBR GreenERTM dye in a 200-μl PCR tube (rxn vol-
ume = 25 μl). All RT-PCR reagents were from Invitrogen and
the samples were run for 40 cycles in a 96-well plate. All results
were expressed relative to glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) and a cellular RNA sample without reverse
transcription was run as a negative control to test for genomic
DNA. cT values were determined by the apparatus and the quality
of the PCR product was conﬁrmed by analyzing the melt-curve.
RT-PCR primers were custom-designed for all murine11 HDAC
genes based on the mouse gene sequences according to published
rat HDAC RT primers (Morrison et al., 2006), Gja1, Gja5, Gapdh,
and Cdh2 (Ncad) murine genes (Lin et al., 2010). RT-PCR primers
were designed to span exon–intron regions of the gene of interest
or by custom ordering primer sets from realtimeprimers.com.
Oligonucleotide primer sequences for the RT-PCR assays of
murine HDAC1-11, Cx43, Cx40, Ncad, and GAPDH gene
expression were: Hdac1, forward 5′-TGGGGCTGGCAAAGG
CAA-3′, reverse 5′-TGGGGCAGCATCCTCAAGTCC-3′; Hdac2,
forward 5′-CGGACAAAAG AATTTCCATTCG-3′, reverse 5′-
CAATGTCCTCAAACAGGGAAG-3′;Hdac3, forward 5′-CCGCT-
TCCATTCTGAGGACTAC-3′, reverse 5′-GACCCGGTCAGTGA-
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GGTAGAAG-3′; Hdac4, forward 5′-GTTCCAGCGTCAACATGA-
G-3′, reverse 5′-GTTGAGAACAAACTCCTG CAGCT-3′; Hdac5,
forward 5′-GCCAGCACCGAGGTAAGGCT-3′, reverse 5′-TTAC-
GGAGG GGAAAGTCATCA-3′; Hdac6, forward 5′-ACCACCTC-
TCTGGAGGCTT-3′, reverse 5′-TGG GGTCACAGCATAAAATA-
CATC-3′; Hdac7, forward 5′-AACTTCGGCAACTTCTCAATAA-
3′, reverse 5′-GGGTGTGCTGCTACTACTGGG-3′; Hdac8, for-
ward 5′-ATGGCCACCTTCCA CACTG-3′, reverse 5′-CTTTGCA-
TGATGCCACCCTC-3′;Hdac9, forward 5′-ATGCCTGTGGTGG-
ATCCTGT-3′, reverse 5′-AGAGGAGGAAGCTGCTGCTC-3′;
Hdac10, forward 5′-TGG CACCGCTATGAGCAT-3′, reverse
5′-GACACCAGCACCAACTCAGG-3′; Hdac11, forward 5′-
GGCAGCGAAGGTAACATCTA-3′, reverse 5′-CACATCCTCTT-
ACCCCTGTG-3′;Gja1, forward 5′-GAGAGCCCGAACTCTCCT-
TT-3′, reverse5′-TGGAGTAGGCTTGGACCTTG-3′; Gja5, for-
ward 5′-CAGAGCCTGAAGAAGCCAAC-3′, reverse 5′-GCAAC-
CAGGCTGAATG GTAT-3′; Cdhc2, forward 5′-TATGTGATGAC-
GGTCACTGC-3′, reverse 5′-GAAAGGCCAT AAGTGGGATT-
3′; and Gapdh, forward 5′-TGCCACTCAGAAGACTGTGG-3′,
reverse 5′-AGGAATGGGAGTTGCTGTTG-3′.
WESTERN BLOTTING
Ventricular myocytes were cultured at high density in 35 mm cul-
ture dishes for 4 days in 3 ml of BrDU/M199 media, harvested, and
lysed with 1% Triton X-100 extraction buffer (50 mM Tris pH 8.0,
150 mM NaCl, 0.02% sodium azide, 1.0 mM phenylmethanesul-
fonylﬂuoride (PMSF), 1 μg/ml aprotinin, 1% Triton X-100, 1 mM
Na3VO4, 50 mM sodium ﬂuoride (NaF) with protease inhibitors
(Roche). One dish from each primary culture served as a control
sample and a second dish was treated with either TSA or VOR for
24 h prior to harvesting. Sonicated samples (three 30-s pulses)
were incubated on ice for 30 min, centrifuged at 14,000 rpm
(10 min at 4◦C), transferred to new tubes, and protein concen-
trations were measured using the coomassie blue protein assay
(Bio-Rad). Fifteen micrograms of total protein/sample was heated
(55◦C) and loaded onto an SDS-PAGE (sodium dodecyl sulfate
polyacrylamide gel electrophoresis) gel and electrophoresed for
90min at 110V in 4×NuPAGE sampling buffer and 10×NuPAGE
reducing buffer (Invitrogen). The protein gels were transferred
onto polyvinylidene diﬂuoride (PVDF) membranes for 90 min
at 4◦C (110 V), blocked with 5% non-fat milk for 1 h at room
temperature, and incubated overnight at 4◦C with Cx43, Ncad,
α-tubulin, or α-actin primary antibodies in phosphate-buffered
saline (PBS) with Tween 20 (PBS-T) with 5% non-fat milk.
The membranes were washed 5 min × 4 with PBS-T, incubated
with horseradish peroxidase (HRP)-labeled secondary antibody
(1:5000) at room temperature in PBS-T with 5% non-fat milk
for 30 min, washed again 5 min × 4 with PBS-T, and developed
using the ECLTM Western Blot Detection Reagents (Bio-Rad). The
image was taken by exposuring light sensitive ﬁlms (Midsci) to
the PVDF membrane and developing the ﬁlms using the Auto-
developer (Kodak) in a dark room. The density of the bands was
quantiﬁed using ImageJ. Primary antibodies used in this study
include rabbit anti-Cx43 (Chemicon), mouse anti-Cx43 (Zymed),
mouse anti-Cx40 (Zymed), mouse anti-α-tubulin (Sigma), rab-
bit anti-acetylated-α-tubulin (Enzo),mouse anti-α-actin antibody
(Sigma), rabbit anti-acetylated lysine antibody (Abcam), andNcad
(Sigma). pSer-speciﬁc Cx43 antibodies were produced as previ-
ously described including rabbit anti-pS255 (Santa Cruz; Sirnes
et al., 2009), rabbit anti-pS262 (Santa Cruz; Srisakuldee et al.,
2006), rabbit anti-pS279/282 (Santa Cruz; Arnold et al., 2005;
Solan and Lampe, 2008), rabbit anti-pS325/328/330 (Lampe et al.,
2006), rabbit anti-pS365 (Solan et al., 2007), rabbit anti-pS368
(R&D; Solan et al., 2007), and rabbit anti-pS373 (P. D. Lampe,
personal communication, manuscript in preparation).
IMMUNOSTAINING, IMAGING, AND ANALYSIS
Ventricular myocytes were cultured at high density on 10 μg/ml
ﬁbronectin-coated 18 mm diameter glass coverslips in 12-well
plates with 1 ml of BrDU/M199 media for 4 days. Control
and TSA- or VOR-treated myocyte cultures were ﬁxed with 4%
paraformaldehyde, permeabilized with 1% Triton X-100 in PBS,
and blocked by the addition of 2% goat serum at room tempera-
ture for 15 min. Primary mouse anti-Cx43 antibody (Invitrogen)
was diluted 1:500 in 2% goat serum/1% Triton X-100/PBS, 250 μl
added to each coverslip, and incubated overnight at 4◦C according
to previously published procedures (Lin et al., 2010). Coverslips
were washed three times with PBS, incubated in the dark with
Alexa Fluor546 goat anti-mouse secondary antibodies (1:1500
dilution) for 3 h at room temperature, washed three times with
PBS, stained with 4′,6-diamidino-2-phenylindole (DAPI) for 5–
10 min, rinsed twice with PBS and ﬁnally with distilled, deionized
water and mounted onto glass slides with the Prolong Gold
antifade medium (Invitrogen).
Confocal ﬂuorescence micrographs for the TSA experiments
were acquired using theZeiss LSM510METAconfocalmicroscope
core facility and viewed using the Zeiss LSM Image Browser V3.5
software. Confocal ﬂuorescence micrographs for the VOR experi-
ments were acquired using the Perkin-Elmer UltraView Vox dual
spinning disk confocal microscope facility located in the Cell and
Developmental Biology Department of State University of New
York Upstate Medical University. Optical sections were acquired
with 0.5 μm resolution (≈ 1λ since ﬂuorophore is Alexa Fluor546
(nm) and one section from the center of the Z-stack represent-
ing the highest GJ area was exported as a TIF ﬁle, imported into
ImageJ, converted to 8-bit red color, background subtracted using
the ﬂuorescence intensity histogram (10–25%, average ≈ 10%),
and converted to black-on-white bitmaps of Cx43 immunoﬂuo-
rescent regions in ImageJ based on the methods of Hunter et al.
(2005). Only conﬂuent ventricular cell monolayer regions were
imaged and ﬁve regions per coverslip were sampled. Each experi-
ment was repeated three times, resulting in 15 analyzed images per
[TSA] or [VOR] experiment. GJ area was expressed as the % of
immunolocalized Cx43 area per total area of each image and each
experiment was performed on cultured glass coverslips treated
with 0, 20, 50, or 100 nM TSA or 0, 0.2, 0.5, 1.0, or 5.0 μM VOR
prepared from the same ventricular myocyte primary culture.
CHROMATIN IMMUNOPRECIPITATION ASSAY
Ventricularmyocytes were seeded at high density in 35mmculture
dishes, cultured for 4 days in BrDU/M199media, treated overnight
with 2 μMVOR,ﬁxed with 1% formaldehyde, collected and stored
in −80◦C for chromatin immunoprecipitation (ChIP) assay. ChIP
assays were carried out using the ChIPAssay kit (Millipore Catalog
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#17-295) according to the manufactures procedures. The cells
were lysed with SDS lysis buffer (1% SDS, 10 mM ethylenedi-
aminetetraacetic acid (EDTA), 50 mM Tris, 1 mM PMSF, 1 μg/ml
aprotinin, and 1 μg/ml pepstatin A, pH 8.1, sonicated to shear
the chromatin DNA to 400–1000 bp, diluted 10-fold in ChIP
dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA,
16.7 mM Tris–HCl, 167 mM NaCl, 1 mM PMSF, 1 μg/ml apro-
tinin, and 1 μg/ml pepstatin A, pH 8.1), and pre-cleared with
50 μl protein A agarose/salmon sperm DNA (supplied with the
kit) for 30 min at 4◦C. The pre-cleared cell lysis was immuno-
precipitated with 10 μg of rabbit anti-HDAC1 antibody (Enzo
Life Sciences), rabbit anti-HDAC2 antibody (Enzo Life Sciences),
rabbit anti-Sp1 antibody (Santa Cruz), rabbit anti-RNA Pol II
antibody (Santa Cruz), or normal rabbit IgG (Sigma) overnight
(4◦C). 50 μl of protein A agarose/salmon sperm DNA was added
the next morning and incubated for 1 h at 4◦C. The agarose
was pelleted by centrifugation at 1000 rpm for 1 min, the pel-
lets were washed with low salt buffer (0.1% SDS, 1% Triton X-100,
2 mM EDTA, 20 mM Tris–HCl, 150 mM NaCl pH 8.1), high
salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM
Tris–HCl, 500 mM NaCl pH 8.1), LiCl buffer (0.25 M LiCl, 1%
IGEPAL-CA630, 1% deoxycholic acid, 1 mM EDTA, 10 mM Tris,
pH 8.1), and TE buffer (1 mM EDTA, 10 mM Tris, pH 8.0).
The agarose/protein/DNA complex was eluted with 250 μl elu-
tion buffer (0.1 M NaHCO3, 1% SDS), at room temperature for
15 min and the elution step was repeated once. Twenty microliters
of 5 mol/l NaCl was added to the 500 μl elution solution, and
heated for 4 h at 65◦C to reverse protein–DNA crosslinks. Ten
microliters of 0.5 M EDTA, 20 μl of 1 M Tris–HCl (pH 6.5), and
2 μl of 10 mg/ml proteinase K was added to the elution solution
and incubated 1 h at 45◦C. The DNA in the elution was puriﬁed
with GENECLEAN II Kit (MP) and tested by PCR ampliﬁcation
for 26 cycles. Primers speciﬁc for the mouse Cx43 promoter were:
primer set-1 of 5′-TCCCATGCCCACCGCCTCTT-3′ (sense) and
5′-TGCGGGGCTGTGACTCCTCA-3′ (antisense) corresponding
to nucleotide positions −511 to −492 bp and −225 to −206 bp;
primer set-2 of 5′-TGAGGAGTCACAGCCCCGCA-3′ (sense) and
5′-TCCCTCACGCCTTTCCCCCA-3′ (antisense) corresponding
to nucleotide positions −225 to −206 bp and +65 to +84 bp,
with respect to the transcription start site of Cx43.
ELECTROPHYSIOLOGY
Dual whole cell patch clamp experiments were performed on iso-
lated ventricular myocyte cell pairs as previously described (Lin
et al., 2005, 2008a, 2010). The initial GJ conductance (g j) was
measured immediately upon establishment of the dual whole
cell patch clamp conﬁguration from the linear slope portion
of a 2-s −100 to +100 mV transjunctional voltage (V j) ramp.
Ventricular GJ channel activity was recorded during 30-s V j
pulses ranging from ±20 to ±60 mV. All points current ampli-
tude histograms were produced from each junctional current (I j)
recording and ﬁtted with Gaussian distributions in Origin7.5 to
determine themeanGJ channel current (ij) amplitudes. The linear
slope of the cumulative ij–V j relationship from three experiments
was used to calculate the single GJ channel conductance (γj).
Steady state V j-dependent inactivation (increasing V j) and recov-
ery (decreasing V j) normalized junctional conductance–voltage
(Gj–V j) curves were obtained using a 200 ms/mV, ±120 mV
voltage ramp protocol. Quantitative junctional voltage series
resistance errors were corrected for each patch electrode by the
expression (Veenstra, 2001):
gj = −I2
V1 − (I1 · Rel1) − V2 + (I2 · Rel2) , (1)
where V 1 and V 2 are the command potentials applied to cells 1
and 2, I1 and I2 are the correspondingwhole cell currents,Rel1 and
Rel2 are the corresponding whole cell patch electrode resistances,
and −ΔI2 is the change in I2 recorded with constant V 2 during
a voltage step applied to V 1 (ΔV 1; Veenstra, 2001). I j is assumed
to originate from the ΔV 1 pulse with the same polarity, therefore
I j = I2 − ΔI2. The resultant inactivation and recovery Gj–V j







A · (Vj − V½))] + Gssmin
1 + [exp (A · (Vj − V½))]
]
, (2)
whereGssj = g j/g j,max,Gssmax = themaximumvalue of g j/g j,max = 1,
Gssmin = the minimum value of g j/g j,max, A = the slope factor
for the Boltzmann curve (= zF/RT at 20◦C), and V½ = the half-
inactivation voltage. The actual g j,max value is determined from the
linear slope conductance of the I j–V j relationship for each exper-
iment. The I j–V j relationship is typically linear between ±10 and
±25 mV. Curve-ﬁtting procedures were performed using Clampﬁt
software (pClamp version 8.2, Axon Instruments, Inc.) and ﬁnal
graphs were prepared using Origin version 7.5 software (Origin-
LabCorporation,Northampton,MA,USA). Tetrodotoxin (30μM
TTX, Sigma) was added to the bath saline (mM:NaCl 142, KCl 1.3;
CsCl 4, TEACl 2, MgSO4 0.8, NaH2PO4 0.9, CaCl2 1.8, dextrose
5.5, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
10, pH 7.4 with 1 N NaOH) of each dish to prevent activation of
the sodium current during the dual whole cell patch clamp experi-
ments. Patch pipettes measuring 4–5 MΩ before patch break were
ﬁlled with a KCl internal pipette solution (IPS KCl, in mM: KCl,
140; MgCl2, 1.0; CaCl2, 3.0; 1,2 bis(o-amino-phenoxy)ethane-
N,N,N′,N′-tetra acetic acid (BAPTA), 5.0; HEPES, 25; pH titrated
to 7.4 using 1 N KOH). The osmolarity of both external and
internal solutions was adjusted to 310 mOsm/l.
STATISTICAL ANALYSIS
One-way ANOVA was performed on multiple experimental
datasets in Origin7.5 with the Levene’s test for equal variance and
the Bonferroni means comparison test. Actual p values are shown
in the ﬁgures when statistically signiﬁcant (p < 0.05)
RESULTS
HDAC EXPRESSION AND INHIBITION IN CULTURED VENTRICULAR
MYOCYTES
The relative expression of all 11 HDACs in neonatal mouse
ventricular myocyte cultures was examined by RT-PCR. HDAC
mRNA levels ranged from 1 to 16% relative to Cx43 mRNA levels
(Figure 1A). Cx40 mRNA levels were 1.6 ± 0.7% (mean ± SEM)
relative to Cx43, indicative of contributions from the ventric-
ular conduction system and coronary endothelial cells. The
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same relative HDAC mRNA expression pattern was found in
atrial cardiomyocyte cultures wherein the Cx40 mRNA level was
38.4 ± 5.9%, consistent with the contribution of Cx40 to atrial
myocardial GJs (Figure 1A; Lin et al., 2010). TSA, the prototyp-
ical hydroxamic acid pan-HDACI, suppressed ventricular HDAC
activity with apparent inhibitory equilibrium constants (K Is) of
12 and 174 nM (Figure 1B). HeLa cells exogenously expressing
Cx43 (stable HeLa-Cx43 cells) exhibited a single K I of 510 nM.
VOR, by comparison, inhibited ventricular cardiac HDAC activ-
ity with approximately 10-fold higher K Is of 186 and 1440 nM
(Figure 1C). HeLa-Cx43 cell inhibition by VOR also exhibited a
dual afﬁnity proﬁle withK Is of 300 nM and 2 μM.Ventricular car-
diomyocyte total HDAC activity declined to a minimum of 2–6%
with TSA or VOR inhibition.
TRICHOSTATIN A AND VORINOSTAT AFFECT Cx43 mRNA AND PROTEIN
EXPRESSION
Since protein acetylation is known to alter gene expression, we
examined the effect of HDAC inhibition by TSA and VOR on
Cx43 mRNA and protein expression levels by RT-PCR and west-
ern blot analyses. The lowest doses of TSA and VOR tested did
not signiﬁcantly change Cx43 mRNA expression, though further
increases in [TSA] or [VOR] produced a progressive decline in
Cx43 mRNA levels to a minimum of 13% relative to untreated
control values (Figures 2A,B). One micromolar VOR reduced
the Cx43 mRNA expression levels by 54%. The transcriptional
effects of HDACI by TSA or VOR were veriﬁed at the trans-
lational level by western blot analysis of Cx43 (Figures 2C–F).
Acetylated α-tubulin levels increased with both TSA and VOR.
Densitometry scans of three HDACI western blot experiments
conﬁrm a gradual dose-dependent reduction in the amount of
Cx43 protein to aminimumof 5–12%of control levels by TSA and
VOR. The recommended therapeutic dose of 1 μM VOR reduced
Cx43 protein levels by an average of 60 ± 3%. Ncad mRNA and
protein levels were reduced by ≈30% (Figures 3A,B; Kerr et al.,
2010). This dose of VOR also reduced atrial cardiomyocyte Cx40
protein expression by 64 ± 6% (Figures 3C,D). The Cx43 and
Cx40 levels relative to the α-tubulin loading controls were similar,
1.26 ± 0.30 for Cx43 (n = 3, mean ± SEM) and 1.26 ± 0.26
for Cx40 (n = 4). We further examined whether ventricular
HDAC inhibition by 1 μM VOR could affect the phosphorylation
state of Cx43 using custom and commercially available pSer-
speciﬁc Cx43 antibodies. Western blot analysis of seven identiﬁed
Cx43 pSer sites revealed altered protein kinase-dependent Cx43
phosphorylation content relative to control levels. Since total
Cx43 was downregulated by HDACI treatment, the phospho/total
Cx43 ratios of the treated samples were normalized to the phos-
pho/total ratios of the control samples to analyze the changes
of pSer levels by VOR. The results indicated additional down-
regulation of phosphorylation at S255 (pS255) by 57.9 ± 4.9%.
Conversely, the phosphorylation of S325/328/330 was upregu-
lated by 48.5 ± 19.8% in presence of 1 μM VOR. The pS262,
pS279/282, pS365, pS368, and pS373 levels were not signiﬁcantly
altered (Figures 4A,B).
HDACI ALTERS PROTEIN BINDING TO THE Cx43 PROMOTER REGION
To examine whetherVOR induced repression of Cx43 (Gja1) gene
expression by altering protein binding to the proximal promoter
of Cx43 in heart, ChIP assays were performed to examine the
association of Sp1 (speciﬁcity protein 1) and RNA polymerase
II (RNA Pol II) with the Gja1 promoter. Up to 0.5 kb of the
Gja1 promoter containing one TATA and several GC boxes was
examined by PCR using two sets of primers (Figure 5A). Primer
set-1 speciﬁcally ampliﬁed the −511 to −206 bp and primer set-
2 speciﬁcally recognized −225 to +65 bp of the Gja1 promoter
region. The results indicate that 2 μM VOR decreased association
of Sp1 and RNA Pol II with the Cx43 promoter (Figures 5B,C).
Gja1 promoter association with Sp1 was detected by primer set-
1 while only primer set-2 detected RNA Pol II association. The
association of HDAC1 and 2with theGja1 promoterwas increased
by VOR treatment (Figures 5D,E). The expression of HDAC1, 2,
Sp1, and RNA Pol II were not altered by VOR.
HDACI DECREASES Cx43 GAP JUNCTION AREA
Since TSA and VOR reduced Cx43 mRNA and protein levels, we
examined whether HDACI also affected the formation of Cx43
GJs between cultured ventricular myocytes. Cx43 was immunolo-
calized in cardiomyocytes after culturing on glass coverslips for
3 days and overnight TSA or VOR treatments. Five micrographs
of conﬂuent ﬁelds from each coverslip were imaged on a confo-
cal microscope and the Cx43 immunolabeled area was quantiﬁed
using ImageJ (Figures 6A–H). Each [TSA] and [VOR] experiment
was repeated three times and the maximum % of Cx43 GJ area was
tabulated for each HDACI concentration. Again, the lowest dose
of TSA or VOR produced a modest increase in Cx43 GJ area fol-
lowed by a progressive dose-dependent decrease in GJ area to a
minimum of 25% relative to control values (Figures 6I,J).
FUNCTIONAL CONSEQUENCES OF HDAC INHIBITION ON VENTRICULAR
GAP JUNCTIONS
Gap junction conductance
To examine whether the downregulation of Cx43 expression and
GJ assembly by pan-HDACI translates into functional alterations
of electrical coupling, the effects of TSA and VOR on functional
Cx43-mediated GJ electrical coupling was studied in dual whole
cell patch experiments of isolated ventricular myocyte cell pairs.
The GJ conductance (g j) was measured at the onset of dual
whole patch clamp recordings of junctional current (I j) in ven-
tricular myocyte cultures treated overnight with TSA or VOR
(Figures 6K,L). Increasing concentrations of TSA produced a
progressive decline in electrical coupling between ventricular car-
diomyocytes that achieved statistical signiﬁcance above 35 nM.
VOR produced a slight increase in electrical coupling at 200 nM
followedby a gradual decrease in ventricular g j. The recommended
therapeutic dose of 1 μM VOR reduced ventricular gj by 20%
(p < 0.05). Maximal HDAC inhibition by TSA (≥100 nM) orVOR
(5 μM) produced signiﬁcant 40–50% decreases in ventricular g j.
Transjunctional voltage gating
We previously described the steady state transjunctional voltage
(V j) gating of ventricular GJs using continuous 24 s, ±120 mV
V j staircase and reported the phenomenon of a higher slope g j
during the return (declining) phase of the V j staircase termed
facilitation (Figure 7A; Lin et al., 2005). TSA reduced the
amplitude of this increased Gj during the recovery phase in a
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FIGURE 2 | Dose-dependent alteration of Cx43 expression by pan-HDACI.
(A,B) Real-time PCR results of Cx43 mRNA expression levels after
overnight inhibition by increasing [TSA] (A) and [VOR] (B) relative to control
(untreated) values. Experiments were performed in triplicate and
the lowest dose of both pan-HDACI produced an insigniﬁcant increase in
average Cx43 mRNA levels and a signiﬁcant reduction in Cx43 mRNA
levels at the highest doses. (C,D) Representative Cx43 western blots of
ventricular cell lysates fromTSA (C) or VOR (D) treated cultures. (E,F)
Statistical analysis of the protein densitometry scans from three
experiments reveal signiﬁcant dose-dependent reductions in Cx43 protein
content. Cx43 protein levels were normalized to a control sample from
each experiment with α-tubulin (αT) expression used as an internal
control and acetylated α-tubulin (Ac-αT) as a positive indicator for HDAC
inhibition.
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FIGURE 3 | Reduction of Cx40 and N-cadherin expression by HDACI.
(A) Overnight (18 h) treatment with 1 μMVOR signiﬁcantly reduced Cx43
and N-cadherin mRNA levels by 45 ± 5 and 30 ± 6%, respectively.
Experimental mean values were statistically different from control values
(p-value < 0.05, one-way ANOVA). (B) Immunoblots were also performed
for Ncad and β-actin (internal control). Total Ncad levels from three
experiments were decreased by 1 μMVOR relative to control (untreated)
samples. (C) Representative Cx40 western blots of atrial cell lysates from
control or 1 μMVOR-treated cultures. (D) Statistical analysis of the protein
densitometry scans from four experiments reveals a signiﬁcant reduction in
Cx40 protein content. Cx40 protein levels were normalized to a control
sample from each experiment with α-tubulin expression used as an internal
control and acetylated α-tubulin (Ac-αT) as a positive indicator for HDAC
inhibition.
dose-dependent manner, eliminating any increase in recovery Gj
when [TSA] ≥ 100 nM (Figures 7B,C). VOR also abolished Gj
facilitation in a dose-dependent manner (Figures 7G,H). TSA and
VOR also slightly altered the V j-dependent inactivation proper-
ties of ventricular GJs. TSA increased the half-inactivation voltage
(V½) of the inactivation and recovery Gj–V j curves by 10–15 mV
with a slight reduction in theV j-insensitive Gj component (Gmin)
from 0.40 to 0.25 (Table 1). VOR also shifted the V½ values
outward by 5–10 mV. The kinetics of time-dependent inactiva-
tion were examined for varying [TSA] by exponentially ﬁtting
the I j curves to determine the fast and slow decay time constants
(τfast and τslow; Figures 7D–F). The fast and slow inactivation
on-rates (K fast and K slow) were calculated using the equation
K = (1 − Popen)/τdecay . The K fast and K slow values increased
exponentially every 20.9 ± 1.4 or 20.0 ± 1.2 mV, respectively, and
were not altered byTSA.However, the amplitude of theK slow inac-
tivation component decreased progressively with increasing TSA
concentrations.
Single gap junction channel conductance
From twenty 100-nM TSA ventricular cell pair recordings, single
GJ channel currents could be resolved in only three poorly coupled
ventricular myocyte cell pairs. GJ channel current (ij) amplitudes
corresponding to low (30–50 pS), intermediate (60–80 pS), and
high (90–110 pS) channel conductance (γj) states were observed
in untreated cardiomyocyte cell pairs, consistent with previous
observations for Cx43 and ventricular GJ channels (Moreno et al.,
1994). In the three 100-nM TSA experiments, ventricular γj was
reduced to 54 pS, corresponding to only the low γj state of Cx43
GJ channels. The 80 pS state was still evident in the presence of
5 μM VOR (Figure 8).
DISCUSSION
Our results show that the atrial and ventricular myocardial HDAC
expression pattern is similar. Therefore, any differential effects
of a particular HDACI on atrial or ventricular excitability and
contractility will depend primarily on the expression of ion chan-
nels, transporter, junctional, and contractile proteins unique to
the specialized regions of the mammalian heart. The cell-based
HDAC activity assay also indicates thatVOR inhibits total myocar-
dial HDAC activity with two apparent afﬁnities of approximately
200 nM and 1.4 μM (Figure 1C). The nanomolar higher capac-
ity site falls within the recommended serum therapeutic range for
VOR of ≤1 μM (400 mg/day) and likely corresponds to inhibition
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FIGURE 4 | Alteration of Cx43 phosphorylation state by vorinostat. (A)
Representative western blot of control and 1 μMVOR-treated ventricular
myocyte lysates detected with Cx43 phospho-serine (pSer) speciﬁc
anti-pS255, anti-pS262, anti-pS279/282, anti-pS368, anti-pS325/328/330,
anti-pS365, and anti-pS373 antibodies. The total Cx43 was also
immunoblotted with an anti-Cx43 carboxyl-terminal antibody that
recognizes all forms of Cx43. (B) Cx43 phospho-serine pS255, pS262,
pS279/282, pS368, pS325/328/330, pS365, and pS373 levels were
compared by densitometry to the total Cx43 levels in control and 1 μM
VOR-treated samples to generate the phospho/total Cx43 ratios. The
VOR-treated phospho/total Cx43 ratios are plotted relative to control Cx43
phospho/total ratio.
of the class I HDACs (HDAC1–3 and 8) and the class IIb HDAC6
(Bradner et al., 2010; Kerr et al., 2010). This is important because
the reductions in ventricular Cx43 expression and electrical cou-
pling observed in our experiments are not signiﬁcant until the
concentration of VOR meets or exceeds this 1 μM therapeutic
value. This dose of VOR lowered Ncad protein content by 33%,
Cx43 protein content by approximately 50%, GJ area by 33%, and
ventricular g j by less than 20% (Figures 2, 3, and 6). The signif-
icant reduction in Ncad and functional Cx43 GJ expression may
result from occupying the micromolar afﬁnity HDAC site, which
could correlate with inhibition of the class IIa HDACs (HDAC4,
FIGURE 5 | Alteration of Cx43 promoter associated proteins by
vorinostat. (A) Illustration of the Cx43 promoter region up to −0.5 kb from
the Cx43 gene (Gja1) transcription start site of Cx43 with TATA and GC
boxes indicated. Two primer sets were designed from −511 to −206 and
−225 to +65 bp of the Cx43 promoter region. (B,C) Chromatin
immunoprecipitation assays illustrate the reduced binding of RNA
polymerase II (RNA Pol II) and speciﬁc protein 1 (Sp1) to the promoter
region of Cx43 after overnight exposure to 2 μMVOR. (D,E) A chromatin
immunoprecipitation assay was performed with rabbit IgG and rabbit
anti-HDAC1 or anti-HDAC2 antibodies to assess the binding of HDAC1 (D)
and HDAC2 (E) to the promoter region of the Cx43 gene (Gja1). Overnight
treatment with 2 μMVOR enhanced the association of HDAC1 and HDAC2
to the Gja1 promoter.
5, 7, and 9) since the K I of VOR for these HDACs is nearly 10-fold
higher (Bradner et al., 2010). We intend to study the differential
effects of speciﬁc class I, IIb, and IIa HDAC inhibition on myocar-
dial expression and function using class-selective HDACIs like
MS-275 or MGCD-0103, tubastatin, and MC-1568, respectively
(Mai et al., 2005; Rasheed et al., 2007; Bradner et al., 2010; Butler
et al., 2010).
These reductions in cardiac intercalated disk adhesion and
communicating junctions may not affect conduction velocity or
promote arrhythmias since a 50% global loss of Cx43 content
minimally alters myocardial conduction velocity or the incidence
of sustained ventricular tachycardias (Danik et al., 2004). How-
ever, heterogeneous loss of >80% of Cx43 expression leads to
ventricular systolic dysfunction and increased susceptibility to
lethal ventricular arrhythmias (Gutstein et al., 2001). Chronic
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FIGURE 6 | Measurement of Cx43 GJ area and ventricular electrical
coupling. (A–H) Representative confocal images of mouse primary anti-Cx43
and goat anti-mouse Alexa Fluor 546 secondary antibody immunolocalized
Cx43 gap junction plaques from 4-day ventricular myocyte cultures (A,C,E,G)
and their corresponding black-on-white bitmaps of the Cx43-positive pixels
(B,D,F,H). The total GJ area was calculated relative to the total image area of
the conﬂuent monolayer cardiomyocyte cluster. Five clusters were imaged
per coverslip and each experiment was repeated in triplicate for each [TSA]
and [VOR]. (I,J) Statistical analysis of the average Cx43 GJ area values
(±SEM, n = 15) at each pan-HDACI concentration revealed a signiﬁcant
decrease in GJ area for [TSA] ≥ 50 nM and [VOR] ≥ 500 nM. (K,L) Initial gap
junction conductance (g j ) measurements, upon establishment of the dual
whole cell patch clamp conﬁguration, from numerous (n = 14–34) cell pairs
revealed a dose-dependent maximum decrease in ventricular g j of 40–50%
by pan-HDACI. The decline in ventricular g j was statistically signiﬁcant for
[TSA] ≥ 35 nM and [VOR] ≥ 1 μM.
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FIGURE 7 | Continued
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FIGURE 7 | Continued
V j-dependent gating of ventricular gap junctions during HDAC
inhibition. A 200 ms/mV V j ramp from 0 to ±120 mV was applied to patch
clamped ventricular myocyte pairs and V j was returned to 0 mV by ramp
reversal to produce the normalized junctional conductance–voltage (Gj–V j )
inactivation and recovery curves. The black line represents the normalized g j
during the increasing V j (inactivation) ramp and the gray line is the Gj–V j
curve obtained during the decreasing V j (recovery) ramp. The facilitated
recovery of g j was observed as an increase in the normalized g j (Gj ) of the
recovery curve relative to the initial slope g j of the ventricular gap junctions
during the increasing (inactivation) phase of the V j ramp (inactivation curve
normalized slope g j = 1.0). The smooth black and gray lines are Boltzmann
equation ﬁts of the ventricular Gj–V j curves obtained from ﬁve to six
experiments from control myocytes (A), 100 nMTSA-treated myocytes (B),
or 1 μMVOR (G). The parameters for the Boltzmann ﬁts of the 100 nMTSA
and 1 μMVOR Gj–V j inactivation and recovery curves are listed inTable 1.
(C)The slope Gj of the recovery Gj–V j curves was increased in normal
ventricular myocytes and abolished byTSA treatments in a dose-dependent
manner. (D)The inactivation kinetics were determined in control and
TSA-treated ventricular myocyte pairs by ensemble averaging the I j from 5
to 10 V j pulses from −70 to −140 mV. The ensemble averaged I j trace was
ﬁtted with a second-order decaying function and the fast and slow
inactivation rates were calculated from the expression
kon = (1 − Popen)/τdecay. One example is shown for a control (black line)
and 100 nMTSA-treated (gray line) myocyte pair in response to a train of
−120 mV V j pulses. (E,F)The fast (E) and slow (F) on-rates for hypothesized
inactivation particles were plotted relative to the absolute value of the V j
pulses and ﬁtted with ﬁrst-order exponential increasing functions. The fast
inactivation rates were not affected byTSA while the amplitude, but not the
V j -dependence, of the slow inactivation rates were progressively reduced
by increasingTSA concentrations. (G)The smooth black and gray lines are
Boltzmann equation ﬁts of the ventricular Gj–V j curves obtained from ﬁve
1.0 μMVOR-treated myocyte pairs (seeTable 1). (H)The slope Gj of the
recovery Gj–V j curves, increased under normal conditions, was abolished
by VOR treatments in a dose-dependent manner.
heart failure (CHF) and myocardial infarction (MI) also reduces
Cx43 content and remodels GJ connections, potentially predispos-
ing the myocardium to reentrant arrhythmias (Luke and Safﬁtz,
1991; Kostin et al., 2003). There are no reports of QT interval pro-
longation or cardiac arrhythmias occurring with VOR (Rasheed
et al., 2007), even with single dose administration of twice (i.e.,
800 mg/day) the normal therapeutic dose of VOR in 24 patients
with advanced malignancies (Munster et al., 2009). QT interval
prolongation and associated risk for torsades de pointes (TdP)
ventricular tachyarrhythmias were reported in clinical trials with
two hydroxamic acid-derived HDACIs, LAQ-824 and LBH-589
(Rasheed et al., 2007). Romidepsin, a tricyclic peptide HDACI, has
resulted in corrected QT (QTc) interval prolongation and sud-
den cardiac death from probable fatal ventricular arrhythmias
(Shah et al., 2006; Rasheed et al., 2007). The mechanistic basis
for these cardiac arrhythmias remains essentially unknown since
preliminary studies suggest that human ether-a-go-go potassium
channel (Kv11.1) protein (HERG) blockade develops only in the
supra micromolar range for LBH-589 and VOR (Giles et al., 2006;
Kerr et al., 2010).
In general, HDACI is thought to improve Cx43 GJ inter-
cellular communication (GJIC) between cancer cells (Ogawa
et al., 2005; Hernandez et al., 2006). However, HDACIs do not
necessarily increase connexin expression and GJIC, owing to dif-
ferent HDACI activities and fundamental differences between
immortalized cancer cell lines and primary cell cultures (e.g., hep-
atocytes, cardiomyocytes; Vinken et al., 2007). The TSA-induced
increased transcription of Cx43 (Gja1) gene expression requires
positive cooperation between Ap1 and Sp1 elements and is asso-
ciated with hyperacetylated HDAC4 within the 2.4 kb gene
promoter region (Hernandez et al., 2006). We analyzed the prox-
imal 500 bp of the Gja1 gene promoter sequence via ChIP
assay (Figure 5), inclusive of the Sp1 and four Ap1 sites, and
found decreased Sp1 and RNA Pol II and increased HDAC1
and 2 association within this promoter region in the presence
of 2 μM VOR. Lower doses of VOR (e.g., 200 nM) were not
tested. The altered RNA Pol II and HDAC1 and 2 associa-
tions with the Gja1 gene promoter sequence were not previously
described. The HAT P300/CBP associated factor (PCAF), and
HDAC3, 4, and 5 reportedly co-localize with Cx43 in the cytosol
(Colussi et al., 2011). Precise control of Gja1 gene transcription
by HDAC and HDACI activities requires further investigation
using class-speciﬁc HDACIs and/or HDAC gene knockout or
RNAi knockdown strategies. Again, class-speciﬁc HDAC inhi-
bition with second generation HDACIs such as MGCD-0103
or MS-275, tubastatin, and MC-1568 will further delineate the
effects of HDACI on Gja1 gene expression. Preliminary results
from our laboratory with sodium phenylbutyrate, a low afﬁn-
ity HDACI with class I/IIa activities, conversely showed an
increase in Cx43 protein expression (data not shown). Mice
with germline deletion of the class IIa/b HDACs 4–10 are viable
while class I HDAC1–3 knockout mice are embryonic lethal and
require conditional knockout strategies to be studied further.
The impact of pan- and class-selective HDACI or HDAC gene
deletion/knockdown on connexin expression should be studied
in primary tissues to understand the effects of these emerging
HDACI clinical therapies on normal physiology (e.g., cardiac
electrophysiology) in addition to the therapeutics effects under
pathophysiological conditions in cancerous and other diseased
tissues.
Colussi et al. (2010, 2011) did not directly compare the Cx43
expression levels in wt mouse hearts treated with VOR for 96 h
although Cx43 levels were reportedly unchanged in wt or mdx
mouse hearts. Our in vitro results indicate that TSA and VOR
ﬁrst produce a negligible change in Cx43 expression and function
followed by a progressive diminution of Cx43 (and Cx40) expres-
sion and GJIC with increasing concentrations of pan-HDACI.
Increased protein acetylation associated with the mdx mouse or
induced by HDACI treatment of wt mice correlated with Cx43
dissociation from cardiac intercalated disk proteins (e.g., ZO-1,
Ncad) and lateralization (Colussi et al., 2010, 2011). Cx43 lateral-
ization occurs during ischemia and is associated with dephospho-
rylation of Cx43, particularly S325/328/330 and S364/365 sites
(Lampe et al., 2006; Solan et al., 2007; Solan and Lampe, 2009),
and is thought to represent functional GJ downregulation. Colussi
et al. (2011) demonstrated that Cx43 is acetylated and that c-Src-
dependentY265 phosphorylation is increasedwhile S255 and S262
phosphorylation of Cx43 is decreased in mdx mouse hearts. They
did not examine the effects of VOR on wt hearts. Phosphorylation
of Cx43 S262 has been associated with p34cdc42, protein kinase
C (PKC), mitogen-activated protein kinase (MAPK), and v-Src
kinase activity (Solan and Lampe, 2005). Our results indicate that
VOR increases phosphorylated S325/328/330 and decreases phos-
phorylated S255 content while decreasing total ventricular Cx43
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FIGURE 8 | Single gap junction channel conductance (γj) of
HDACI-treated ventricular myocytes. (A) A representative example of
single channel open–closed events during an I j recording in response to a
+60 mV, 30 s V j pulse applied to a pair of primary cultured ventricular
myocytes. Note the activity of low (30–50 pS), intermediate (60–80 pS), and
high (90–110 pS) γj states typical of Cx43 GJ channel activity. (B) An example
of GJ channel activity recorded from a pair of ventricular myocytes treated
with 100 nMTSA during a −40 mV, 30 s V j pulse. Only low (30–50 pS) γj
channel activity was observed in this experiment. (C) Single gap junction
channel current (i j ) amplitudes were measured from all point histograms for
every V j pulse obtained from three different 100 nMTSA-treated ventricular
myocyte cell pairs. Linear regression analysis of the composite i j–V j
relationship had a slope conductance of 54 ± 1 pS. (D) Representative
example of single channel open–closed events during an I j recording in
response to a +40 mV, 30 s V j pulse applied to a pair of primary cultured
ventricular myocytes treated with 5 μMVOR. In two 5 μMVOR-treated
ventricular myocyte pairs, only intermediate 80 pS GJ channel activity was
observed, consistent with the intermediate γj state of Cx43.
expression (Figure 4). Cx43 Y265 phosphorylation was not exam-
ined in our study and should be considered sinceY265, S255, S262,
and S368 phosphorylation downregulate while S325/328/330 and
S364/365 phosphorylation increase Cx43 GJ function (Lampe
et al., 2006; Solan et al., 2007; Solan and Lampe, 2009). Cancer
cells may downregulate Cx43 GJIC by reducing expression and/or
c-Src and MAPK phosphorylation of Cx43 and altering the phos-
phorylation state of Cx43 is another mechanism by which HDACI
may improve GJIC in malignant tissues.
Direct acetylation may also alter the localization of Cx43 since a
triple K-to-Q acetyl-mimetic mutant of Cx43 was predominantly
maintained in the cytoplasm whereas the K-to-A acetylation-
resistant mutant Cx43 readily formed GJ plaques of unknown
function (Colussi et al., 2011). We are presently studying the bio-
physical GJ gating and channel properties of the putative Cx43 K9,
K234, and K264 acetyl-mimetic and -resistant mutations, indi-
vidually and in combination, to determine the possible effects
of Cx43 Nε-lysine acetylation on Cx43 GJ formation and func-
tion. Our ventricular myocyte patch clamp experiments revealed
concentration-dependent decreases in functional GJ coupling
and altered V j-dependent gating properties with TSA and VOR
(Figure 7; Table 1). Ventricular γj was reduced only by high doses
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of TSA (Figure 8), perhaps because of the higher potency TSA
for class IIa inhibition relative to VOR (Bradner et al., 2010). The
pan-HDACI-induced decrease in ventricular g j probably results
from the decreased Cx43 expression and GJ area, which results
in a reduced number of GJ channels (N), since the channel open
probability (Po) was only slightly affected by the changes in V j-
dependent gating, γj was reduced only by high doses of TSA,
and g j = N .Po.γj. We hypothesize that the acetylation-induced
changes in γj and V j-gating may be due to direct acetylation of
Cx43 amino-terminal (K9) and carboxyl-terminal (K234, K264)
lysine residues since these cytoplasmic domains have been impli-
cated in these respectiveGJ channel functions (Moreno et al., 2002;
Musa et al., 2004). Post-translational acetylation may affect the
Cx43 half-life since lysine ubiquitination is a major degradation
pathway for Cx43 GJIC (Kjenseth et al., 2010).
Limitations of the present study include the lack of correlative
in vivo Cx43 expression and GJ localization results, not normal-
izing the immunolabeled Cx43 GJ area to cell membrane area by
co-staining with ﬂuorescently conjugated wheat germ agglutinin,
and no assessment of pan-HDACI effects on myocardial conduc-
tion velocity or susceptibility to arrhythmias. Our supply of VOR
for these initial functional GJ studies was restricted to in vitro
use only by the terms of the MTA agreement. Future HDACI
studies will include in vivo expression and electrocardiogram
parameter (e.g., heart rate, QT interval) monitoring. In vitro con-
duction velocity measurements were not possible because we do
not presently have access to a multi-electrode array (MEA) system.
We hope to provide functional correlates like conduction veloc-
ity and the occurrence of spontaneous ventricular contractions,
tachycardias, or arrhythmias in future investigations.
In conclusion, the present study demonstrates, for the ﬁrst
time, that pan-HDAC inhibition produces dose-dependent reduc-
tions in Gja1 transcription, Cx43 protein content, Cx43 pSer
content, Cx43 GJ area, and functional electrical coupling in nor-
mal mammalian ventricular myocardium with lesser effects on
V j-dependent gating and γj properties. These inhibitory effects
on ventricular g j correlate with VOR inhibition of myocardial
HDAC activity in the micromolar range and suggest inhibi-
tion of class IIa HDACs in combination with class I and IIb
HDACs may be responsible for these potentially adverse effects.
VOR therapy is not associated with the induction of cardiac
arrhythmias observed in clinical trials with three different pan-
HDACIs, but these results suggest that more potent pan-HDAC
inhibitory proﬁles may be more likely to cause adverse cardiac
effects, including reduced myocardial electrical communication,
that may predispose the heart to potentially fatal arrhythmias.
Further investigations of class-selective HDACIs are necessary
to understand the underlying mechanisms for arrhythmogenic
adverse cardiac effects and improved cardiac safety proﬁles for this
emerging class of novel therapeutics with diverse beneﬁcial clinical
indications.
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